BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology
Rhea-AI Summary
BillionToOne (Nasdaq: BLLN) named Allen Chen, MD, MBA, FASTRO, FACHE, as Vice President of Medical Affairs and Clinical Development, Oncology, effective April 2, 2026. Dr. Chen brings more than 20 years of physician-executive experience and will lead clinical and translational strategy for the company's Northstar oncology portfolio.
The company also announced that Gary Palmer, MD, is retiring as Chief Medical Officer, Oncology, and will remain in a CMO emeritus advisory role as BillionToOne advances its Northstar Select (84-gene ctDNA panel) and Northstar Response (methylation-based pan-cancer assay).
Positive
- Appointment of Dr Allen Chen as VP Medical Affairs (Apr 2, 2026)
- Dr Chen brings >20 years of physician-executive and clinical-trial leadership
- Northstar Select is an 84-gene ultra-sensitive single-molecule ctDNA panel
- Northstar Response offers methylation-based, tissue-free pan-cancer response monitoring
Negative
- Chief Medical Officer Gary Palmer is retiring, prompting a leadership transition risk
Key Figures
Market Reality Check
Peers on Argus
No peers are listed in the provided sector and momentum context, and scanner data shows no concurrent peer moves, suggesting a company-specific reaction.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 06 | Clinical collaboration update | Positive | -0.1% | Northstar Select chosen as new liquid biopsy test for LC-SCRUM-TRY study. |
Limited tag-specific history: the prior positive clinical-trial announcement saw a mildly negative move, indicating occasional divergence between upbeat oncology news and short-term price action.
Over recent months, BillionToOne has highlighted the clinical strength of its Northstar liquid biopsy platform, including selection of Northstar Select as the liquid biopsy test for the LC-SCRUM-TRY study in Japan. That clinically positive update saw only a slight share decline. Against that backdrop, the appointment of a seasoned oncology leader to guide medical affairs and clinical development reinforces the company’s ongoing push to expand its oncology testing footprint and clinical trial integration.
Historical Comparison
In the past 6 months, BLLN had 1 clinical‑trial–tagged update with an average move of -0.13%. Today’s +5.09% reaction to an oncology leadership appointment is notably stronger.
Clinical activity has evolved from Northstar Select’s adoption in a major LC-SCRUM-TRY trial to strengthening oncology leadership to support broader clinical and translational research.
Market Pulse Summary
This announcement centers on strengthening BillionToOne’s oncology leadership as Dr. Allen Chen assumes responsibility for medical affairs and clinical and translational research around the Northstar portfolio. It reinforces ongoing efforts to expand liquid biopsy use in solid tumors, complementing earlier clinical-trial adoption updates. Investors may watch for new study collaborations, clinical data readouts, and traction for Northstar Select and Northstar Response as key markers of how this leadership change translates into future oncology growth.
Key Terms
liquid biopsy medical
ctdna medical
methylation-based medical
pan-cancer medical
ngs-based technical
AI-generated analysis. Not financial advice.
Renowned physician executive and clinician-scientist joins BillionToOne to advance oncology medical strategy
Dr. Chen brings more than 20 years of experience as a physician-executive, clinician-scientist, and internationally recognized thought leader across academic and community health systems. Dr. Chen joins BillionToOne following a distinguished career across leading academic medical centers, including the University of California Davis, UCLA's David Geffen School of Medicine, the University of Kansas Cancer Center, and the University of California Irvine, where he was appointed tenured Professor and served in senior leadership positions including Chair of Radiation Oncology, Residency and Fellowship Training Director, and Head of the Protocol Activation and Review Committee for Clinical Trials. Dr. Chen holds an MD from Yale School of Medicine, double MBAs from National University of
"Allen is an exceptional physician leader who has spent more than two decades building cancer programs at major academic medical centers and driving impressive clinical transformation at health systems," said Oguzhan Atay, PhD, co-founder and CEO of BillionToOne. "His deep expertise in cancer care, translational research, and clinical trial leadership is precisely what we need as we scale our oncology mission."
Throughout his career, Dr. Chen has served as principal investigator for dozens of clinical trials, held leadership roles within national cooperative cancer groups, and contributed to National Cancer Institute task forces focused on clinical trial development for patients with metastatic cancer, treatment-refractory disease, and rare tumors. He has authored more than 300 peer-reviewed publications spanning cancer research, health policy, and healthcare delivery. He is also a strong advocate of AI and has implemented technology solutions focused on digital health and machine learning that transformed care programs at medical centers.
"BillionToOne is doing something genuinely impactful by making ultra-sensitive, clinically actionable genomic information accessible to oncologists," said Dr. Chen. "I have spent my career working to close gaps in personalized cancer care delivery, and BillionToOne is truly moving the needle for patients with solid tumors. I am honored to join at this pivotal moment and help oncologists understand and trust the power of these tools. It is such an exciting time in cancer care, and the work happening at BillionToOne is not only groundbreaking but has the potential to change the future."
In his new role, Dr. Chen will lead medical affairs strategy as well as clinical and translational research development for BillionToOne's
Dr. Gary Palmer to Retire, Continuing with BillionToOne in a CMO Emeritus Advisory Role
BillionToOne also announced that Gary Palmer, MD, is retiring as Chief Medical Officer, Oncology. During his tenure, Dr. Palmer played a central role in establishing BillionToOne's clinical strategy in oncology and shaping the clinical foundation of the
"Gary has been a foundational voice in everything we have built in oncology, and his fingerprints are on so much of what makes
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of federal securities laws. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements in this press release include, but are not limited to, statements regarding the scalability of the company's oncology mission. These statements are based on management's current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, some of which are beyond BillionToOne's control. These and additional risks and uncertainties could affect BillionToOne's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. These risks and uncertainties include, but are not limited to, the potential growth relating to the company's oncology products as well as those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in BillionToOne's most recently filed Annual Report on Form 10K and other filings that the company makes with the Securities and Exchange Commission from time to time. The forward-looking statements in this press release are based on information available to BillionToOne as of the date hereof, and BillionToOne disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing BillionToOne's views as of any date subsequent to the date of this press release.
About BillionToOne
Headquartered in
Media Contact
billiontoone@moxiegrouppr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/billiontoone-appoints-dr-allen-chen-as-vice-president-of-medical-affairs-and-clinical-development-oncology-302732288.html
SOURCE BillionToOne
FAQ
Who is Allen Chen and what role did he take at BillionToOne (BLLN) on April 2, 2026?
What are Northstar Select and Northstar Response described by BillionToOne (BLLN)?
What change occurred to BillionToOne's oncology leadership with Gary Palmer on April 2, 2026?
How will Dr Chen's background influence BillionToOne's oncology clinical development (BLLN)?
Does BillionToOne (BLLN) say Dr Chen will work on translational research and medical affairs?
